Lost 17 lbs in 4 wks
When is the right time to apply to DoD SBIR programs
GHK-Cu and Skin Remodeling: Updated Clinical Evidence. *J
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
From a scientific standpoint, GHK-Cu remains the better-validated compound
The most recent demonstration of the impact of BPC 157 on vasomotor tone was carried out through BPC 157-specific activation of the Src-caveolin-1-endothelial NO synthase (eNOS) pathway (Hsieh et al., 2020)
